Operating results overview
Net sales
|
Operating income
|
Ordinary income
|
Profit attributable to owners of parent
|
Net income per
share
|
109,109 million yen (Increase year-on- year by 11.4%)
|
11,160 million yen (Increase year-on- year by 134.1%)
|
11,666 million yen (Increase year-on- year by 40.3%)
|
5,974 million yen (Decrease year-on- year by 1.9%)
|
36.21 Yen
|
Profit attributable to owners of parent
During the first half of this consolidated fiscal year (April 1 to September 30, 2024), the global economy saw a trend of improvement despite uncertainties such as the persistent high level of geopolitical risk and the downturns in economic growth in Europe and China.
The Nippon Kayaku Group entered the third year of KAYAKU Vision 2025, the mid-term business plan which began in fiscal year ended March 31, 2023, amid such conditions. We continue to implement the roadmap to the vision specified for each business while advancing initiatives to address key company-wide issues aimed at achieving the vision.
As a result, net sales for the first half of this consolidated fiscal year totaled 10,919 million yen, an increase of 11,200 million yen (11.4%) year-on-year. Sales in the Life Science Business Unit underperformed slightly while sales in the Mobility & Imaging Business Unit and Fine Chemicals Business Unit outperformed the first half of the previous fiscal year.
Operating income outperformed the first half the previous fiscal year in all segments’ profit, reaching 11,160 million yen, an increase of 6,393 million yen (134.1%) year-on-year.
Ordinary income totaled 11,666 million yen, an increase of 3,352 million yen (40.3%) year-on-year. Profit attributable to owners of parent was 5,974 million yen, a decrease of 118 million yen (1.9%) year-on-year, due to the impact of a valuation loss on investment securities.
Performance by business segment
1. Mobility & Imaging
Operating income by business segment
Sales rose to 45,996 million yen, an increase of 6,528 million yen (16.5%) year-on-year.
In the safety systems business, problems with irregularities in certificates of conformance caused a slump in automobile production in Japan. This caused sales of airbag inflators and micro gas generators for seatbelt pretensioners to underperform year-on-year.
Overseas, sales for China were firm, while automobile demand in the main ASEAN markets in Indonesia and Thailand declined due to stricter auto loan screening. Overseas sales of airbag inflators, micro gas generators for seatbelt pretensioners, and squibs all outperformed year-on-year as sales were boosted by increasing yen weakness. The safety systems business overall outperformed year-on-year as a result.
The Polatechno business outperformed year-on-year as demand for components for X-ray analysis systems remained firm and was also boosted by gains from yen weakness. Polarizing films outperformed year-on-year, owing to the price changes on some products implemented in the previous period. The Polatechno business overall outperformed year-on-year as a result.
Segment profit totaled 7,025 million yen, an increase of 3,706 million yen (111.7%) year-on-year. This increase was due to growth in sales in both businesses.
2. Fine Chemicals
Operating income by business segment
Sales rose to 32,618 million yen, an increase of 4,674 million yen (16.7%) year-on-year.
The functional materials business as a whole outperformed the first half of the previous fiscal year. This outperformance resulted from firm demand for epoxy resins and other products groups as the semiconductor market rebounded.
The color materials business as a whole outperformed the first half of the previous fiscal year. This outperformance resulted from firm sales of industrial inkjet ink, home inkjet printer colorants, and developer for thermal paper.
Slow sales caused the catalyst business to underperform the first half of the previous fiscal year.
Segment profit totaled 4,904 million yen, an increase of 2,650 million yen (117.6%) year-on-year. The increase stemmed from growth in sales in the functional materials and color materials businesses.
3. Life Science
Operating income by business segment
Sales were 30,495 million yen, a decrease of 2 million yen (0.0%) year-on-year.
In the pharmaceuticals business, pharmaceuticals for the Japanese domestic market outperformed the first half of the previous fiscal year due to strong sales of BEVACIZUMAB BS, ADALIMUMAB BS, and other biosimilars, and firm demand for cancer-related generics. Sales of active pharmaceutical ingredients for the Japanese domestic market, exports, sales from contract production, and diagnostic drugs underperformed the first half of the previous fiscal year, resulting in year-on-year underperformance for the pharmaceuticals business as a whole.
The agrochemicals business as a whole outperformed the first half of the previous fiscal year due to the year-on-year increase in domestic sales, despite underperformance in exports.
Sales in the real estate were on par with the first half of the previous fiscal year.
Segment profit totaled 3,589 million yen, an increase of 502 million yen (16.3%) year-on-year.